|
|
Vaccine Detail
|
Pentacel |
| Vaccine Information |
- Vaccine Name: Pentacel
- Target Pathogen: Haemophilus influenzae
- Target Disease: Meningitis
- Product Name: Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate (Tetanus Toxoid Conjugate) Vaccine
- Tradename: Pentacel
- Manufacturer: Sanofi Pasteur Ltd
- Vaccine Ontology ID: VO_0000084
- CDC CVX code: 120
- Type: Subunit vaccine + Inactivated or "killed" vaccine
- Status: Licensed
- Location Licensed: USA (License #1726), Canada
- Host Species for Licensed Use: Human
- Adjuvant:
- Preservative: 2 phenoxy ethanol
- Allergen: Polymyxin B, Neomycin
- Preparation: Corynebacterium diphtheriae is grown in modified Mueller’s growth medium. After purification by ammonium sulfate fractionation, the diphtheria toxin is detoxified with formaldehyde and diafiltered (FDA: Pentacel).
- Immunization Route: Intramuscular injection (i.m.)
- Storage: Store at 2° to 8°C (35° to 46°F). Do not freeze.
- Approved Age for Licensed Use: 6 weeks to 4 years of age.
- Contraindication: A severe allergic reaction (e.g., anaphylaxis) after a previous dose of Pentacel vaccine, any ingredient of this vaccine, or any other tetanus toxoid, diphtheria toxoid, pertussis-containing vaccine, inactivated poliovirus vaccine or H influenzae type b vaccine is a contraindication (FDA: Pentacel).
- Description: It consists of a Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus (DTaP-IPV) component and an ActHIB® vaccine component. Pentacel vaccine is indicated for active immunization against diphtheria, tetanus, pertussis, poliomyelitis and invasive disease due to Haemophilus influenzae type b (FDA: Pentacel).
|
| Host Response |
|
|
| References |
FDA: Pentacel: FDA: Pentacel [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm172502.htm]
|
|
